NCI-H596 In Vitro High-throughput Screening (HTS) Assay

This assay is to provide NCI-H596-based In Vitro High-throughput Screening (HTS) Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

NCI-H596

Human

The NCI-H596 cell line was derived by A.F. Gazdar and H. Oie in 1983 from a tumor mass in the chest wall of a patient with adenosquamous carcinoma of the lung. The specimen was obtained prior to therapy.

Adenosquamous Carcinoma

Oncology

In Vitro High-throughput Screening (HTS) Assay

HTS is one of the modern technologies used in cancer drug discovery. This technique enables to screen or assay thousands of chemical compounds against a target of interest within a short period. HTS is also useful in screening different libraries such as synthetic compounds, combinatorial chemistry, peptides and genomic libraries and obtaining toxicological and pharmacokinetic data related to chemical compounds. HTS has gained much attention among scientists and industries as a large number of compounds prepared by chemical synthesis methods can be screened within a short period, which can reduce the cost of drug discovery and animal use. HTS consist of major steps such as identification of targets, preparation of reagents, management of test compounds, development of suitable assay procedures and screening.

High-throughput Screening, High Content Screening and Reporter Gene Assays